Feb 28, 2018 9:25am EST Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson
Feb 22, 2018 8:00am EST Can Fite Announces the Submission of Safety Reports for Piclidenoson and Namodenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile
Feb 12, 2018 7:00am EST Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson
Jan 25, 2018 7:00am EST Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries
Jan 08, 2018 7:40am EST Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings
Jan 03, 2018 7:00am EST Can-Fite Enters into Collaborative Research Agreement with Hadassah Medical Center to Further Explore Namodenoson Mechanism of Action in NASH
Dec 18, 2017 7:00am EST Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson
Nov 27, 2017 7:30am EST Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update
